Mirzaten (Mirtazapine)

Mirtazapine, the active ingredient in Mirzaten, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as an oral tablet for oral use. It is indicated for the treatment of major depressive disorder in adult patients. GNH USA supplies Mirzaten as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirtazapine is a NaSSA antidepressant that acts on depressive disorders and related symptom clusters.

Major depressive disorder: improves mood, sleep and appetite in adult patients. Depressive episodes with insomnia: provides sedative effect that can aid sleep while treating depression. Depressive episodes with anxiety: reduces anxiety symptoms alongside core depressive relief.

Mirtazapine may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Sedation or somnolence - Increased appetite and weight gain - Dry mouth - Constipation - Dizziness - Fatigue

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Seizures - Hepatic injury or jaundice - Suicidal thoughts or behavior - Severe hypersensitivity reactions (e.g., Stevens‑Johnson syndrome) - Orthostatic hypotension

Before initiating therapy, clinicians should consider several safety aspects.

Monitor weight: patients often experience increased appetite and weight gain. Assess hepatic function: use with caution in patients with liver impairment. Screen for suicidal ideation: especially during early treatment phases. Avoid abrupt discontinuation: taper dose to reduce withdrawal symptoms. Store at ambient temperature: keep below 25 °C, retain in original packaging, and protect from moisture.

Mirtazapine can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - MAO inhibitors: risk of hypertensive crisis; avoid concurrent use. - Linezolid or other reversible MAO inhibitors: potential serotonin syndrome. - Other serotonergic antidepressants: increased serotonin syndrome risk.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (e.g., fluoxetine): may raise mirtazapine plasma levels. - CYP3A4 inducers (e.g., carbamazepine): may reduce therapeutic exposure. - Alcohol: can enhance central nervous system depression.